Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Inovio Pharmaceuticals Inc (NASDAQ:INO)

9.27
Delayed Data
As of Aug 29
 +0.41 / +4.63%
Today’s Change
4.50
Today|||52-Week Range
11.69
+37.95%
Year-to-Date
Inovio (INO) Stock Climbs, Launches Zika Vaccine Trial
Aug 29 / TheStreet.com - Paid Partner Content
3 Reasons Inovio Pharmaceuticals Inc. Stock Could Rise
Aug 19 / MotleyFool.com - Paid Partner Content
4 Stocks for Fighting Zika
Aug 25 / TheStreet.com - Paid Partner Content
Inovio (INO) Veterinary Vaccine Rights Licensed to Plumbline
Aug 17 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close8.86
Today’s open9.19
Day’s range9.12 - 9.55
Volume2,831,707
Average volume (3 months)1,565,201
Market cap$651.6M
Dividend yield--
Data as of 08/29/2016

Growth & Valuation

Earnings growth (last year)+31.25%
Earnings growth (this year)--
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+288.00%
P/E ratioNM
Price/Sales11.32
Price/Book3.64

Competitors

 Today’s
change
Today’s
% change
VNDAVanda Pharmaceutical...-0.07-0.46%
DVAXDynavax Technologies...+0.02+0.12%
GBTGlobal Blood Therape...-0.11-0.60%
AIMTAimmune Therapeutics...+0.14+0.95%
Data as of 08/29/2016

Financials

Next reporting dateNovember 7, 2016
EPS forecast (this quarter)-$0.27
Annual revenue (last year)$40.6M
Annual profit (last year)-$29.2M
Net profit margin-71.94%

Profile

Sector
Health Technology
Industry
Medical Specialties
President, Chief Executive Officer &
Director
J. Joseph Kim
Chief Operating Officer
Niranjan Y. Sardesai
Corporate headquarters
Plymouth Meeting, Pennsylvania

Forecasts

Partner Offers

Search for Jobs